Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing hematologic malignancies, but how to translate this success to solid malignancies remains elusive. Effective translation of CAR T cells to solid tumors will require an understanding of potential therapeutic barriers, including factors that regulate CAR T cells expansion, persistence, trafficking, and fate within tumors. Herein, we describe the current state of CAR T cells in solid tumors; define key barriers to CAR T cell efficacy and mechanisms underlying these barriers, outline potential avenues for overcoming these therapeutic obstacles, and discuss the future of translating CAR T cells for the treatment of patients with solid malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Tumors can be classified broadly based on their degree of T cell infiltration and to date, those tumors demonstrating active T cell penetration appear more likely to respond to immunotherapy (Tumeh et al., 2014).”
BackgroundChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 2×
“…CAR T cells have demonstrated potent activity in B cell acute lymphoblastic leukemia as well as B cell lymphomas (e.g., chronic lymphocytic leukemia and nonHodgkin lymphoma) (Porter et al., 2011; Grupp et al., 2013; Davila et al., 2014; Maude et al., 2014; Lee et al., 2015; Brudno et al., 2016).”
BackgroundInnate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 4×
“This personalized medicine approach has produced promising results for many patients across a range of hematological malignancies (Porter et al., 2011; Kochenderfer et al., 2012; Brentjens et al., 2013; Gill & June, 2015).”
BackgroundInfluentialChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“…CAR T cells have demonstrated potent activity in B cell acute lymphoblastic leukemia as well as B cell lymphomas (e.g., chronic lymphocytic leukemia and nonHodgkin lymphoma) (Porter et al., 2011; Grupp et al., 2013; Davila et al., 2014; Maude et al., 2014; Lee et al., 2015; Brudno et al., 2016).”
BackgroundLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898 · cited 3×
“For example, the manufacturing failure rate among patients treated with CD19-redirected CAR T cells is approximately 5–10% (Davila et al., 2014; Lee et al., 2015; Porter et al., 2015).”
BackgroundCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“For example, CCL2 is commonly produced within tumors and acts to recruit myeloid cells to the tumor microenvironment (Qian et al., 2011).”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“Activation of the β-catenin pathway can also modulate the chemokine profile of tumors by preventing expression of CCL4, which appears to be important for dendritic cell recruitment and subsequent T cell priming and activation in draining lymph nodes (Spranger et al., 2015).”
BackgroundCSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 1×
“CSF1R inhibitors have also been reported to shift the biology of tumor-infiltrating myeloid cells from pro- to anti-tumor (Pyonteck et al., 2013).”
BackgroundFeig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 1×
“This personalized medicine approach has produced promising results for many patients across a range of hematological malignancies (Porter et al., 2011; Kochenderfer et al., 2012; Brentjens et al., 2013; Gill & June, 2015).”
BackgroundRegulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“…including (i) enhanced metabolism and subsequent depletion of amino acids (e.g. arginine and tryptophan) that are important for T cell function (Bronte & Zanovello, 2005; Munn & Mellor, 2007) and (ii) hypoxia and a resultant extracellular matrix acidification due to insufficient vascular…”
BackgroundPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“In addition, the vasculature that feeds tumors is commonly dysregulated with poorly arranged and tortuous vessels that ineffectively supply the tumor bed with nutrients thereby leading to regional hypoxia and acidosis (Huang et al., 2013; Jain, 2014).”
BackgroundLoss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript caspase 9 fused to a modified FK-binding domain undergo apoptosis when exposed to AP1903, a small-molecule dimerizing drug (Straathof et al., 2005; Di Stasi et al., 2011).”
BackgroundHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 1×
“Disruption of VEGF/VEGFR2 signaling can induce vascular normalization in tumors (Huang et al., 2012).”
BackgroundImmune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · cited 4×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript (Gajewski et al., 2013; Beatty & Gladney, 2015; Joyce & Fearon, 2015).”
BackgroundInfluentialSelf-citationAhmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004 · cited 3×
“…of CAR T cells against malignant cells residing in solid tissues is consistent with many other reports investigating CAR T cells in sarcoma (Ahmed et al., 2015), glioblastoma (O’Rourke et al., 2015), ovarian (Kershaw et al., 2006), pancreatic (Beatty et al., 2014a; Beatty et al., 2015a),…”
MethodResultInfluentialBayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“Immature myeloid cells recruited to solid malignancies have been shown to suppress T cell activation, and their elimination can restore T cell accumulation within tumors (Bayne et al., 2012; Stromnes et al., 2014).”
BackgroundSelf-citationShrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669 · cited 1×
“In addition, the vasculature that feeds tumors is commonly dysregulated with poorly arranged and tortuous vessels that ineffectively supply the tumor bed with nutrients thereby leading to regional hypoxia and acidosis (Huang et al., 2013; Jain, 2014).”
BackgroundIbrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474 · cited 1×
“For example, the BTK inhibitor ibrutinib has recently been shown to improve CAR T cell engraftment and enhance CAR T cell activity in xenograft models (Fraietta et al., 2016).”
BackgroundEarly memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Singh, N., Perazzelli, J., Grupp, S. A., & Barrett, D. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5222 · Cited by 303 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript with enhanced expansion capacity (Singh et al., 2016).”
BackgroundMolecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Cited by
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
Beatty, G. L., O’Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.029 · Cited by 514
Self-citationTchou, J., Zhao, Y., Levine, B. L., Zhang, P. J., Davis, M. M., Melenhorst, J. J., Kulikovskaya, I., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 452
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Self-citationHaas, A. R., Tanyi, J. L., O’Hara, M. H., Gladney, W. L., Lacey, S. F., Torigian, D. A., Soulen, M. C., Tian, L., McGarvey, M., Nelson, A. M., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.015 · Cited by 380
Self-citation
Metadata
- Authors
- Beatty, G. L., & O'Hara, M.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 166
- Pages
- 30-39
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2462177828
- Cited by
- 130
- References
- 25
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.